By proceeding, you agree to our Terms of Use and Privacy Policy.
Dr. Nimgaonkar is the president and CEO of Glyscend Therapeutics, a venture-backed biopharmaceutical company developing novel orally-delivered compounds that work on targets inside the GI tract to treat a variety of metabolic disorders, including T2D.
Talks About #metabolicdisorders #diseases #Medicine #Healthcare
Preferred Locations #NorthAmerica
Welcome to the 6th Obesity & NASH Drug Development Summit There has been a rise and fall of investment in NASH in the wake of highly demanding biopsy endpoints and late-stage clinical setbacks.
